• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利福布汀对小鼠中的脓肿分枝杆菌有效。

Rifabutin Is Active against Mycobacterium abscessus in Mice.

机构信息

Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.

Department of Medical Sciences, Hackensack Meridian School of Medicine at Seton Hall University, Nutley, New Jersey, USA.

出版信息

Antimicrob Agents Chemother. 2020 Jan 27;64(2). doi: 10.1128/AAC.01943-19.

DOI:10.1128/AAC.01943-19
PMID:31767722
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6985736/
Abstract

There is no reliable cure for lung disease. Rifampin is not used clinically due to poor potency. In contrast, we have shown that rifabutin, another approved rifamycin used to treat tuberculosis, is potent against Here, we report that rifabutin is as active as clarithromycin against K21 in NOD.CB17-Prkdc/NCrCrl mice. This suggests that rifabutin should be considered a repurposing candidate for patients with disease.

摘要

目前尚无治愈肺病的可靠方法。利福平由于效力不佳,临床上已不再使用。相比之下,我们已经证明,另一种用于治疗结核病的批准利福霉素利福布汀对 具有很强的活性。在这里,我们报告利福布汀对 NOD.CB17-Prkdc/NCrCrl 小鼠中的 具有与克拉霉素相当的活性。这表明利福布汀应该被视为 疾病患者的重新定位候选药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bee/6985736/ba9e728b2da1/AAC.01943-19-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bee/6985736/ba9e728b2da1/AAC.01943-19-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5bee/6985736/ba9e728b2da1/AAC.01943-19-f0001.jpg

相似文献

1
Rifabutin Is Active against Mycobacterium abscessus in Mice.利福布汀对小鼠中的脓肿分枝杆菌有效。
Antimicrob Agents Chemother. 2020 Jan 27;64(2). doi: 10.1128/AAC.01943-19.
2
Synergism of Rifabutin with Clarithromycin, Imipenem, and Tigecycline against the Complex.利福布汀与克拉霉素、亚胺培南和替加环素联合应用对复合体的协同作用。
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02234-18. Print 2019 Apr.
3
Rifabutin Is Active against Mycobacterium abscessus Complex.利福布汀对脓肿分枝杆菌复合群有活性。
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00155-17. Print 2017 Jun.
4
Repositioning rifamycins for Mycobacterium abscessus lung disease.重新定位利福霉素类药物治疗脓肿分枝杆菌肺病。
Expert Opin Drug Discov. 2019 Sep;14(9):867-878. doi: 10.1080/17460441.2019.1629414. Epub 2019 Jun 14.
5
Rifabutin Acts in Synergy and Is Bactericidal with Frontline Mycobacterium abscessus Antibiotics Clarithromycin and Tigecycline, Suggesting a Potent Treatment Combination.利福布丁与一线抗分枝杆菌抗生素克拉霉素和替加环素协同作用并具有杀菌作用,提示这是一种有效的治疗组合。
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00283-18. Print 2018 Aug.
6
Synergy Testing of Eravacycline in Combination with Clarithromycin and Rifabutin against Mycobacterium abscessus Complex.依拉环素与克拉霉素及利福布汀联合对脓肿分枝杆菌复合群的协同试验
Microbiol Spectr. 2021 Sep 3;9(1):e0004521. doi: 10.1128/Spectrum.00045-21. Epub 2021 Jun 16.
7
Vancomycin and Clarithromycin Show Synergy against .万古霉素和克拉霉素对 表现出协同作用。
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01298-17. Print 2017 Dec.
8
In vitro activity of rifabutin against Mycobacterium abscessus, clinical isolates.利福布汀对脓肿分枝杆菌临床分离株的体外活性。
Clin Exp Pharmacol Physiol. 2022 Jul;49(7):767-775. doi: 10.1111/1440-1681.13651. Epub 2022 Jun 5.
9
Nontuberculous Mycobacterial Lung Diseases Caused by Mixed Infection with Mycobacterium avium Complex and Mycobacterium abscessus Complex.非结核分枝杆菌肺病由鸟分枝杆菌复合群和脓肿分枝杆菌复合群混合感染引起。
Antimicrob Agents Chemother. 2018 Sep 24;62(10). doi: 10.1128/AAC.01105-18. Print 2018 Oct.
10
Indole-2-Carboxamides Are Active against in a Mouse Model of Acute Infection.吲哚-2-羧酰胺类化合物在急性感染的小鼠模型中具有活性。
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02245-18. Print 2019 Mar.

引用本文的文献

1
Pathogenicity and virulence of ..的致病性和毒力
Virulence. 2025 Dec;16(1):2508813. doi: 10.1080/21505594.2025.2508813. Epub 2025 May 26.
2
Curcumin enhances bedaquiline's efficacy against : and evidence.姜黄素增强贝达喹啉对……的疗效:以及证据。 (原文表述似乎不太完整,翻译可能不太能完全达意)
Microbiol Spectr. 2025 Mar 18;13(5):e0229524. doi: 10.1128/spectrum.02295-24.
3
Toward better cures for lung disease.寻求更好的肺部疾病治疗方法。

本文引用的文献

1
Repositioning rifamycins for Mycobacterium abscessus lung disease.重新定位利福霉素类药物治疗脓肿分枝杆菌肺病。
Expert Opin Drug Discov. 2019 Sep;14(9):867-878. doi: 10.1080/17460441.2019.1629414. Epub 2019 Jun 14.
2
The Role of Antibiotic-Target-Modifying and Antibiotic-Modifying Enzymes in Drug Resistance.抗生素靶点修饰酶和抗生素修饰酶在耐药性中的作用
Front Microbiol. 2018 Sep 12;9:2179. doi: 10.3389/fmicb.2018.02179. eCollection 2018.
3
Challenges of NTM Drug Development.非结核分枝杆菌药物研发的挑战。
Clin Microbiol Rev. 2024 Dec 10;37(4):e0008023. doi: 10.1128/cmr.00080-23. Epub 2024 Oct 3.
4
Rifabutin central nervous system concentrations in a rabbit model of tuberculous meningitis.利福布汀在结核性脑膜炎兔模型中的中枢神经系统浓度。
Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0078324. doi: 10.1128/aac.00783-24. Epub 2024 Jul 19.
5
Preclinical murine models for the testing of antimicrobials against Mycobacterium abscessus pulmonary infections: Current practices and recommendations.抗分枝杆菌药物治疗脓肿分枝杆菌肺部感染的临床前小鼠模型:当前的实践和建议。
Tuberculosis (Edinb). 2024 Jul;147:102503. doi: 10.1016/j.tube.2024.102503. Epub 2024 Mar 19.
6
Exploring antibiotic resistance mechanisms in for enhanced therapeutic approaches.探索[具体对象]中的抗生素耐药机制以改进治疗方法。 (你提供的原文“Exploring antibiotic resistance mechanisms in for enhanced therapeutic approaches.”中“in for”之间缺少具体内容,我根据语境补充了“[具体对象]”,你可根据实际情况调整)
Front Microbiol. 2024 Feb 6;15:1331508. doi: 10.3389/fmicb.2024.1331508. eCollection 2024.
7
Tackling Nontuberculous Mycobacteria by Repurposable Drugs and Potential Leads from Natural Products.利用可再利用药物和天然产物中的潜在先导化合物来应对非结核分枝杆菌。
Curr Top Med Chem. 2024;24(15):1291-1326. doi: 10.2174/0115680266276938240108060247.
8
Characterization of colony-biofilms based on bi-dimensional images.基于二维图像的菌落生物膜特性分析。
Antimicrob Agents Chemother. 2023 Sep 19;67(9):e0040223. doi: 10.1128/aac.00402-23. Epub 2023 Aug 11.
9
ADP-ribosylation-resistant rifabutin analogs show improved bactericidal activity against drug-tolerant in caseum surrogate.耐 ADP-核糖基化利福布汀类似物对干酪素替代物中耐药结核分枝杆菌具有增强的杀菌活性。
Antimicrob Agents Chemother. 2023 Sep 19;67(9):e0038123. doi: 10.1128/aac.00381-23. Epub 2023 Jul 26.
10
skin and soft tissue infection following autologous fat grafting in Kurdistan treated with an antibiotic combination including Imipenem-Relebactam and Rifabutin.在库尔德斯坦地区,自体脂肪移植后皮肤和软组织感染采用包括亚胺培南-瑞来巴坦和利福布汀的抗生素联合治疗。
J Clin Tuberc Other Mycobact Dis. 2023 Jun 2;32:100381. doi: 10.1016/j.jctube.2023.100381. eCollection 2023 Aug.
Front Microbiol. 2018 Jul 18;9:1613. doi: 10.3389/fmicb.2018.01613. eCollection 2018.
4
Treatment of Mycobacterium avium Complex (MAC).鸟分枝杆菌复合体(MAC)的治疗。
Semin Respir Crit Care Med. 2018 Jun;39(3):351-361. doi: 10.1055/s-0038-1660472. Epub 2018 Aug 2.
5
and Intracellular Activity of Imipenem Combined with Rifabutin and Avibactam against Mycobacterium abscessus.并评估亚胺培南联合利福布汀和阿维巴坦对脓肿分枝杆菌的胞内活性。
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00623-18. Print 2018 Aug.
6
NTM drug discovery: status, gaps and the way forward.NTM 药物发现:现状、差距和未来发展方向。
Drug Discov Today. 2018 Aug;23(8):1502-1519. doi: 10.1016/j.drudis.2018.04.001. Epub 2018 Apr 7.
7
Treatment outcomes of rifabutin-containing regimens for rifabutin-sensitive multidrug-resistant pulmonary tuberculosis.含利福布汀方案治疗利福布汀敏感的耐多药肺结核的治疗结局。
Int J Infect Dis. 2017 Dec;65:135-141. doi: 10.1016/j.ijid.2017.10.013.
8
Rifabutin Is Active against Mycobacterium abscessus Complex.利福布汀对脓肿分枝杆菌复合群有活性。
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00155-17. Print 2017 Jun.
9
Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591.分枝杆菌属脓肿内在的利福霉素耐药性是由 ADP-核糖基转移酶 MAB_0591 介导的。
J Antimicrob Chemother. 2017 Feb;72(2):376-384. doi: 10.1093/jac/dkw466. Epub 2016 Dec 20.
10
Deaths Related to Nontuberculous Mycobacterial Infections in the United States, 1999-2014.1999-2014 年美国与非结核分枝杆菌感染相关的死亡病例。
Ann Am Thorac Soc. 2016 Nov;13(11):1951-1955. doi: 10.1513/AnnalsATS.201606-474BC.